ロード中...

The relationship between preliminary efficacy and prognosis after first-line EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment of advanced non-small cell lung cancer

BACKGROUND: Nowadays, patients with EGFR tyrosine kinase inhibitor (EGFR-TKI)-sensitive advanced non-small cell lung cancer (NSCLC) receive EGFR-TKIs as first-line treatment. We aimed to analyze the relationship between preliminary efficacy (tumor shrinkage within 1 month) and progression-free survi...

詳細記述

保存先:
書誌詳細
出版年:Ann Transl Med
主要な著者: Chen, Dongfang, Chu, Tianqing, Chang, Qing, Zhang, Yanwei, Xiong, Liwen, Qiao, Rong, Teng, Jiajun, Han, Baohui, Zhong, Runbo
フォーマット: Artigo
言語:Inglês
出版事項: AME Publishing Company 2019
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6545314/
https://ncbi.nlm.nih.gov/pubmed/31205913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2019.04.06
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!